The design of clinical trials for new molecularly targeted compounds: Progress and new initiativesSEYMOUR, Lesley.Current pharmaceutical design. 2002, Vol 8, Num 25, pp 2279-2284, issn 1381-6128, 6 p.Article

Anti-cancer agentsSEYMOUR, Lesley K.Current pharmaceutical design. 2002, Vol 8, Num 25, issn 1381-6128, 56 p.Serial Issue

Inhibition of raf kinase in the treatment of acute myeloid leukemiaCRUMP, Michael.Current pharmaceutical design. 2002, Vol 8, Num 25, pp 2243-2248, issn 1381-6128, 6 p.Article

A review of dose-limiting events in phase I trials : antimetabolites show unpredictable relationships between dose and toxicitySEYMOUR, Lesley; EISENHAUER, Elizabeth.Cancer chemotherapy and pharmacology. 2001, Vol 47, Num 1, pp 2-10, issn 0344-5704Article

Rationale for ras and raf-kinase as a target for cancer therapeuticsNOTTAGE, Michelle; SIU, Lillian L.Current pharmaceutical design. 2002, Vol 8, Num 25, pp 2231-2242, issn 1381-6128, 12 p.Article

BAY 43-9006: Preclinical dataWILHELM, Scott; CHIEN, Du-Shieng.Current pharmaceutical design. 2002, Vol 8, Num 25, pp 2255-2257, issn 1381-6128, 3 p.Article

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics : CCRLORUSSO, Patricia M; BOERNER, Scott A; SEYMOUR, Lesley et al.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1710-1718, issn 1078-0432, 9 p.Article

Clinical predictive value of the in vitro Cell line, Human xenograft, and mouse allograft preclinical cancer modelsVOSKOGLOU-NOMIKOS, Theodora; PATER, Joseph L; SEYMOUR, Lesley et al.Clinical cancer research. 2003, Vol 9, Num 11, pp 4227-4239, issn 1078-0432, 13 p.Article

Agents targeting ras signaling pathwayDANCEY, J. E.Current pharmaceutical design. 2002, Vol 8, Num 25, pp 2259-2267, issn 1381-6128, 9 p.Article

Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometryWENJIANG ZHANG; SEYMOUR, Lesley; CHEN, Eric X et al.Journal of chromatography. B. 2008, Vol 876, Num 2, pp 277-282, issn 1570-0232, 6 p.Article

Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan : CCRFORSTER, Martin D; SAIJO, Nagahiro; SEYMOUR, Lesley et al.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1737-1744, issn 1078-0432, 8 p.Article

BAY 43-9006: Early clinical data in patients with advanced solid malignanciesHOTTE, Sebastien J; HIRTE, Hal W.Current pharmaceutical design. 2002, Vol 8, Num 25, pp 2249-2253, issn 1381-6128, 5 p.Article

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approvalGOFFIN, John; BARAL, Stefan; DONGSHENG TU et al.Clinical cancer research. 2005, Vol 11, Num 16, pp 5928-5934, issn 1078-0432, 7 p.Article

Design and discovery of small molecules targeting Raf-1 kinaseLOWINGER, Timothy B; RIEDL, Bernd; DUMAS, Jacques et al.Current pharmaceutical design. 2002, Vol 8, Num 25, pp 2269-2278, issn 1381-6128, 10 p.Article

Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly : An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21WHEATLEY-PRICE, Paul; DING, Keyue; SEYMOUR, Lesley et al.Journal of clinical oncology. 2008, Vol 26, Num 14, pp 2350-2357, issn 0732-183X, 8 p.Article

Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesSEYMOUR, Lesley K; CALVERT, A. Hilary; LOBBEZOO, Marinus W et al.European journal of cancer (1990). 2013, Vol 49, Num 8, pp 1808-1814, issn 0959-8049, 7 p.Article

Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal CancerCHEN, Eric; JONKER, Derek; GAUTHIER, Isabelle et al.Clinical cancer research (Print). 2009, Vol 15, Num 4, pp 1481-1486, issn 1078-0432, 6 p.Article

Alternate Endpoints for Screening Phase II Studies : Phase II Trials: Designs for the futureDHANI, Neesha; DONGSHENG TU; SARGENT, DanielJ et al.Clinical cancer research (Print). 2009, Vol 15, Num 6, pp 1873-1882, issn 1078-0432, 10 p.Article

Gefitinib. CommentariesCULY, Christine R; FAULDS, Diana; GIACCONE, Giuseppe et al.Drugs (Basel). 2002, Vol 62, Num 15, pp 2237-2250, issn 0012-6667, 14 p.Article

Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)NEIL REAUME, M; LEIGHL, Natasha B; PERRONE, Francesco et al.Lung cancer. 2013, Vol 82, Num 1, pp 115-120, issn 0169-5002, 6 p.Article

Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant ChemotherapySHEPHERD, Frances A; DOMERG, Caroline; BOURREDJEM, abderrahmane et al.Journal of clinical oncology. 2013, Vol 31, Num 17, pp 2173-2181, issn 0732-183X, 9 p.Article

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy : National cancer institute of canada clinical trials group study BR.20ARNOLD, Andrew M; SEYMOUR, Lesley; GOSS, Glen-Wood et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4278-4284, issn 0732-183X, 7 p.Article

Erlotinib in lung cancer : Molecular and clinical predictors of outcomeTSAO, Ming-Sound; SAKURADA, Akira; MARRANO, Paula et al.The New England journal of medicine. 2005, Vol 353, Num 2, pp 133-144, issn 0028-4793, 12 p.Article

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : National cancer institute of Canada-clinical trials group study BR.18LEIGHL, Natasha B; PAZ-ARES, Luis; CRAWFORD, Jeffrey et al.Journal of clinical oncology. 2005, Vol 23, Num 12, pp 2831-2839, issn 0732-183X, 9 p.Article

A pharmacodynamic study of the Epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patientsDANESHMAND, Manijeh; PAROLIN, Doris A. E; LORIMER, Ian A. J et al.Clinical cancer research. 2003, Vol 9, Num 7, pp 2457-2464, issn 1078-0432, 8 p.Article